Physician profile
Emily T Klatte
NPI 1548474406
$64,114.60
in general payments reported to CMS, 2019-2025
13 companies · $7,307 in 2025
The $7,307 reported for 2025 was more than what 89% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $4,614 · 2021: $8,606 · 2022: $17K · 2023: $7,226 · 2024: $18K · 2025: $7,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Consulting Fee: $5,864 · Travel and Lodging: $4,628 · Food and Beverage: $2,819 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,644.00 |
| Consulting Fee | $5,863.50 |
| Travel and Lodging | $4,628.46 |
| Food and Beverage | $2,819.45 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $57,190.27 | 2020-2025 | Valtoco |
| Neuropace, INC. | $5,283.86 | 2019-2025 | |
| Sk Life Science, INC. | $662.80 | 2022-2025 | Xcopri |
| Livanova USA, INC. | $298.08 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $256.02 | 2019-2022 | |
| Genzyme Corporation | $136.33 | 2023 | |
| Eisai INC. | $115.57 | 2020 | |
| Zimmer Biomet Holdings, INC. | $56.67 | 2019 | |
| Supernus Pharmaceuticals, INC. | $34.63 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $33.44 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Ceribell, INC. | $15.35 | 2025 | Pocket Eeg Device |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Klatte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.